Diligence memo · auto-generated · as of July 2, 2026
Transplant Genomics Inc.
Transplant Genomics Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Transplant Genomics Inc. operates in Biotech, based in Mansfield.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Transplant Genomics Inc. has raised $21M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.0M on 2018-08-24.
Most recent recorded round closed around 2018-08-24.
Valuation (modeled)modeled
Provath models Transplant Genomics Inc. at approximately $288M (range $8.7M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.26× the median modeled value of Series A Biotech companies in 2016–2018 (8 peers) — value vs value, same stage and era. Within the normal band (126% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 7.9 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 91% of Biotech peers (233 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Montlake Bioscience Inc., Impact Genomics, Inc., Benchling, Inc., Franklin BioScience - Penn LLC, Element Genomics, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.